OACTIVE

twitterlinkedin

OACTIVE

Advanced personalised, multi-scale computer models preventing OsteoArthritis

Osteoarthritis (OA) is a degenerative disease of the  articular cartilage and the most common form of arthritis that causes joint pain, mobility limitation and, thus, reduces independence and overall quality of life. Although the usual population associated with the condition is the elderly (65 years old ranges from 12- 30%), who are mostly inactive, athletes and younger individuals are also susceptible. Whilst the available data have implicated the role of the various modifiable or non-modifiable risk factors in the development and progression of OA, no study has conclusively explored the interaction and integration of other information sets in a patient-specific manner.

The current OACTIVE project intents to make a significant leap forward adopting a multi-scale holistic approach where patient-specific information from various levels, including cell, tissue, organ and whole body will be integrated and combined with information from other sources such as biochemical/inflammatory  biomarkers, behaviour modeling and social/environmental risk factors to generate robust predictors for new personalised interventions for delaying onset and slowing down progression of OA. OACTIVE targets to patient-specific OA prediction and interventions by using a combination of mechanistic, phenomenological  computational models, simulations and big data analytics.

Once constructed, these models will be used to simulate and predict optimal treatments, better diagnostics, and improved patient outcomes. Overcoming the limitation of the current treatment interventions, Augmented Reality empowered interventions will be developed in a personalised framework allowing patients experience the treatment as more enjoyable, resulting in greater motivation, engagement, and training adherence. OACTIVE’s mission is to improve healthcare by transforming and accelerating the OA diagnosis and prediction based on a more comprehensive understanding of disease pathophysiology, dynamics, and patient outcomes.

Project Budget: 4'984'033,75 €

LEITAT Budget: 422'500 €

Financial Framework: Horizon 2020

Contract number: 777159

Start Date: 01/11/2017

End Date: 31/10/2020

Partners:

Contact Manager: M. Passarello

This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement 777159. This publication reflects only the author’s views and the European Union is not liable for any use that may be made of the information contained therein.